dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
They also played "Rooster" with Comes with the Fall vocalist William DuVall and Ann Wilson. The band followed the concert with a short United States club tour named "Finish What We Started", several festival dates in Europe, and a brief tour in Japan. Duff McKagan again joined the band for the reunion tour, playing rhythm guitar on selected songs. During the tour, the band played a 5-minute video tribute to Staley during the changeover from the electric to acoustic set. To coincide with the band's reunion, Sony Music released the long-delayed third Alice in Chains compilation, The Essential Alice in Chains, a double album that includes 28 songs. Jerry Cantrell met William DuVall in Los Angeles in 2000 through a mutual acquaintance who introduced Cantrell to Comes with the Fall's first album. Cantrell started hanging out with the band and occasionally joined them onstage. Between 2001 and 2002, Comes with the Fall was both the opening act on Cantrell's tour for his second solo album, Degradation Trip, and also his backing band, with DuVall singing Staley's parts at the concerts. DuVall joined Alice in Chains as lead singer during the band's reunion concerts in 2006, and made his first public performance with the band at VH1's Decades Rock Live! concert. According to Cantrell, it only took one audition for DuVall to get the gig. For his first rehearsal with the band, DuVall sang "Love, Hate, Love".
=== Cellulose nanofiber plate === A bottom up approach can be used to create a high-performance bulk material with low density, high strength and toughness, and great thermal dimensional stability: cellulose nanofiber plate (CNFP). Cellulose nanofiber hydrogel is created by biosynthesis. The hydrogels can then be treated with a polymer solution or by surface modification and then are hot-pressed at 80 °C. The result is bulk material with excellent machinability. "The ultrafine nanofiber network structure in CNFP results in more extensive hydrogen bonding, the high in-plane orientation, and "three way branching points" of the microfibril networks". This structure gives CNFP its high strength by distributing stress and adding barriers to crack formation and propagation. The weak link in this structure is bond between the pressed layers which can lead to delamination. To reduce delamination, the hydrogel can be treated with silicic acid, which creates strong covalent cross-links between layers during hot pressing.
Another objection questions whether pleasure is the only thing of value for individuals, citing things like virtue, achievement, friendship, and the satisfaction of desires as distinct sources. An influential counterexample to hedonism, proposed by philosopher Robert Nozick (1938–2002), imagines an experience machine that simulates a life filled with pleasures, which would be ideal from the perspective of hedonism. Pointing out that life in this virtual simulation lacks authenticity, Nozick argues that mere pleasure, by itself, is not the only source of value.
In hepatocytes, insulin binding acutely leads to activation of protein phosphatase 2A (PP2A), which dephosphorylates the bifunctional enzyme fructose bisphosphatase-2 (PFKB1), activating the phosphofructokinase-2 (PFK-2) active site. PFK-2 increases production of fructose 2,6-bisphosphate. Fructose 2,6-bisphosphate allosterically activates PFK-1, which favors glycolysis over gluconeogenesis. Increased glycolysis increases the formation of malonyl-CoA, a molecule that can be shunted into lipogenesis and that allosterically inhibits of carnitine palmitoyltransferase I (CPT1), a mitochondrial enzyme necessary for the translocation of fatty acids into the intermembrane space of the mitochondria for fatty acid metabolism. Insulin also influences other body functions, such as vascular compliance and cognition. Once insulin enters the human brain, it enhances learning and memory and benefits verbal memory in particular. Enhancing brain insulin signaling by means of intranasal insulin administration also enhances the acute thermoregulatory and glucoregulatory response to food intake, suggesting that central nervous insulin contributes to the co-ordination of a wide variety of homeostatic or regulatory processes in the human body. Insulin also has stimulatory effects on gonadotropin-releasing hormone from the hypothalamus, thus favoring fertility. Anabolic vs. Reponic Classification Historically, insulin has been broadly classified as an anabolic hormone because it stimulates the synthesis of complex molecules.
===== Adverse effects ===== Due to a wide range of observed side-effects, flibanserin's safety has been called into question. Clinical trials reported adverse reactions including dizziness, nausea, fatigue, and insomnia. Hypotension and central nervous system depression (somnolence) leading to sedation and sleepiness symptoms were also observed. In order to lower the chances of occurrence, the drug is usually prescribed to be taken only once per day before bed. On the other hand, the third stage of the trial suggests that risks are derived from any moderate or strong cytochrome P450 CYP3A4 inhibitors that are often present in antihypertensive drugs, antiretroviral drugs, antibiotics, or fluconazole. An alcohol-interaction study was also carried out. Instead of premenopausal women, the study was on male participants, with the conclusion that alcohol may pose a risk of systolic and diastolic blood pressure reduction to recipients.
Sources: en.wikipedia.org
== Distribution == Cold seeps were discovered in 1983 by Charles Paull and colleagues on the Florida Escarpment in the Gulf of Mexico at a depth of 3,200 meters (10,500 ft). Since then, seeps have been discovered in many other parts of the world's oceans. Most have been grouped into five biogeographic provinces: Gulf of Mexico, Atlantic, Mediterranean, East Pacific, and West Pacific, but cold seeps are also known from under the ice shelf in Antarctica, the Arctic Ocean, the North Sea, Skagerrak, Kattegat, the Gulf of California, the Red Sea, the Indian Ocean, off southern Australia, and in the inland Caspian Sea. In the Pacific Northwest, a cold seep called Pythia's Oasis was discovered in 2015. With the recent discovery of a methane seep in the Southern Ocean, cold seeps are now known in all major oceans. Cold seeps are common along continental margins in areas of high primary productivity and tectonic activity, where crustal deformation and compaction drive emissions of methane-rich fluid. Cold seeps are patchily distributed, and they occur most frequently near ocean margins from intertidal to hadal depths. In Chile, cold seeps are known from the intertidal zone, in Kattegat, the methane seeps are known as "bubbling reefs" and are typically at depths of 0–30 m (0–100 ft), and off northern California, they can be found as shallow as 35–55 m (115–180 ft). Most cold seeps are located considerably deeper, well beyond the reach of ordinary scuba diving, and the deepest seep community known is found in the Japan Trench at a depth of 7,326 m (24,035 ft).
2008–09 - Michael "Michi" Mueller - Puma Ocean Racing 2011–12 - David "Dave" Swete - Team Sanya 2014–15 - Sophie Ciszek - Team SCA 2017–18 - Bleddyn Mon - Turn the Tide on Plastic 2023–23 - Will Harris - Team Malizia
== Biochemistry == The precursors of ketone bodies include fatty acids from adipose tissue or the diet and ketogenic amino acids. The formation of ketone bodies occurs via ketogenesis in the mitochondrial matrix of liver cells. Fatty acids can be released from adipose tissue by adipokine signaling of high glucagon and epinephrine levels and low insulin levels. High glucagon and low insulin correspond to times of low glucose availability such as fasting. Fatty acids bound to coenzyme A allow penetration into mitochondria. Once inside the mitochondrion, the bound fatty acids are used as fuel in cells predominantly through beta oxidation, which cleaves two carbons from the acyl-CoA molecule in every cycle to form acetyl-CoA. Acetyl-CoA enters the citric acid cycle, where it undergoes an aldol condensation with oxaloacetate to form citric acid; citric acid then enters the tricarboxylic acid cycle (TCA), which harvests a very high energy yield per carbon in the original fatty acid.
Mitogen-activated protein kinase 3 (MAPK3) is also known as extracellular signal-regulated kinase 1 (ERK1). Transgenic gene knockout mice lacking MAPK3 are viable and it is thought that MAPK1 can fulfill some MAPK3 functions in most cells. The main exception is in T cells. Mice lacking MAPK3 have reduced T cell development past the CD4+ and CD8+ stage.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.